MYC and Familial prostate cancer: Because of the importance of c-Myc as a downstream contributor to AR’s effects on ligand-independent prostate cancer cell survival, we treated prostate cancer cells with the BET bromodomain inhibitor JQ1, a drug known to suppress expression of bromodomain target genes; foremost among which was c-Myc[22], [23].